-$0.07 Earnings Per Share Expected for Outlook Therapeutics, Inc. (NASDAQ:OTLK) This Quarter

Equities research analysts predict that Outlook Therapeutics, Inc. (NASDAQ:OTLKGet Rating) will announce ($0.07) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Outlook Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.07). Outlook Therapeutics also posted earnings per share of ($0.07) in the same quarter last year. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Outlook Therapeutics will report full year earnings of ($0.29) per share for the current year, with EPS estimates ranging from ($0.31) to ($0.26). For the next year, analysts forecast that the business will post earnings of ($0.10) per share, with EPS estimates ranging from ($0.21) to $0.02. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Outlook Therapeutics.

Outlook Therapeutics (NASDAQ:OTLKGet Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03).

In related news, Director Kurt J. Hilzinger acquired 41,160 shares of the stock in a transaction on Thursday, February 24th. The stock was purchased at an average price of $1.46 per share, for a total transaction of $60,093.60. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of OTLK. Morgan Stanley increased its position in Outlook Therapeutics by 428.2% in the 2nd quarter. Morgan Stanley now owns 124,644 shares of the company’s stock valued at $311,000 after acquiring an additional 101,044 shares in the last quarter. Royal Bank of Canada grew its position in shares of Outlook Therapeutics by 689.0% during the 2nd quarter. Royal Bank of Canada now owns 47,342 shares of the company’s stock worth $118,000 after buying an additional 41,342 shares during the period. Invesco Ltd. acquired a new stake in shares of Outlook Therapeutics during the 2nd quarter worth approximately $58,000. Commonwealth Equity Services LLC acquired a new stake in shares of Outlook Therapeutics during the 3rd quarter worth approximately $46,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Outlook Therapeutics during the 3rd quarter worth approximately $97,000. Hedge funds and other institutional investors own 11.71% of the company’s stock.

OTLK traded down $0.07 during midday trading on Tuesday, hitting $1.50. The company had a trading volume of 417,684 shares, compared to its average volume of 1,237,977. The company has a market capitalization of $338.91 million, a PE ratio of -4.69 and a beta of 0.82. Outlook Therapeutics has a twelve month low of $1.19 and a twelve month high of $3.27. The firm’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $1.59.

Outlook Therapeutics Company Profile (Get Rating)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Featured Articles

Get a free copy of the Zacks research report on Outlook Therapeutics (OTLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.